Twist Bioscience insider files Form 144 to sell 918 vested shares

Rhea-AI Filing Summary

Twist Bioscience (TWST) Form 144 notice: An insider proposes to sell 918 shares of common stock through Fidelity Brokerage Services on 08/21/2025, with an aggregate market value of $23,835.14. The shares were acquired by restricted stock vesting on 08/20/2025 and are being sold as compensation. The issuer has 60,360,925 shares outstanding, making this proposed sale a very small portion of the outstanding shares. The filing also discloses prior insider sales by Adam Laponis of 936 shares on 05/21/2025 (gross proceeds $27,843.57) and 2,449 shares on 07/09/2025 (gross proceeds $93,419.31). The notice includes the standard insider certification that no undisclosed material adverse information is known to the seller.

Positive

• Timely compliance with Rule 144 reporting for proposed and recent insider sales
• Source of shares disclosed (restricted stock vesting) and nature of payment (compensation) provided

Negative

• None.

Insights

Securities Analyst

TL;DR: Insignificant insider sale by vesting restricted stock; disclosure is routine and unlikely to affect market valuation.

The filing shows a proposed sale of 918 shares following restricted stock vesting, with proceeds of $23,835.14, executed through a retail broker. Compared with 60.36 million shares outstanding, the size is immaterial and unlikely to move the stock. Prior sales by the same individual (936 and 2,449 shares) suggest routine post-vesting or liquidity transactions rather than a change in confidence. This is a compliance disclosure under Rule 144; no new operational or financial information about the company is revealed.

Corporate Governance Expert

TL;DR: Proper Rule 144 disclosure for insider sales; documentation of acquisition and payment source supports regulatory compliance.

The form documents that the shares were acquired via restricted stock vesting on 08/20/2025 and sold as compensation on 08/21/2025, which aligns with common executive equity practices. The seller’s certification that no material nonpublic information is known is included, meeting standard attestation requirements. Given the small scale relative to outstanding shares, this filing is a routine governance disclosure and does not indicate material governance or control issues.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	918	23835.14	60360925	08/21/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/20/2025	Restricted Stock Vesting	Issuer			918	08/20/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Adam Laponis 681 Gateway Blvd South San Francisco CA 94080	Common	05/21/2025	936	27843.57
Adam Laponis 681 Gateway Blvd South San Francisco CA 94080	Common	07/09/2025	2449	93419.31

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the TWST Form 144 filing disclose?

The filing discloses a proposed sale of 918 common shares on 08/21/2025 via Fidelity with an aggregate market value of $23,835.14, acquired through restricted stock vesting on 08/20/2025 and sold as compensation.

Who previously sold TWST shares in the past three months according to this filing?

Adam Laponis sold 936 shares on 05/21/2025 for $27,843.57 and 2,449 shares on 07/09/2025 for $93,419.31.

How material is the proposed sale relative to Twist Bioscience's outstanding shares?

The proposed 918-share sale is immaterial versus 60,360,925 shares outstanding, representing a negligible percentage of the float.

How were the shares acquired that are being sold under this Form 144?

The shares were acquired via restricted stock vesting on 08/20/2025 and the transaction is identified as compensation.

Does the filing indicate any undisclosed material information about TWST?

No; the seller has certified they do not know any material adverse information about the issuer that has not been publicly disclosed.